Panic Disorder

Detailed Overview

The disorder significantly impairs quality of life. Patients often visit emergency departments repeatedly believing they are experiencing a myocardial infarction or life-threatening illness. The core psychological feature is 'fear of fear'—the anticipatory anxiety of the next attack. Over time, many patients develop agoraphobia (fear of places where escape might be difficult if an attack occurs), drastically restricting their daily activities. The neurobiology involves hyperactivity of the amygdala and locus coeruleus, with dysregulation of GABAergic, serotonergic, and noradrenergic systems.

Epidemiology & Demographics

Lifetime prevalence is approximately 2-3% in the US. It is roughly twice as common in women as in men. The typical age of onset is late adolescence or early adulthood (median age 20-24), though it can occur in children or older adults.

Etiological Mechanism

A complex interplay of genetic vulnerability and environmental stressors. Heritability is estimated at around 40%. Psychosocial stressors, such as major life transitions or a history of physical or sexual abuse in childhood, frequently precipitate the onset. Carbon dioxide hypersensitivity is a known biological trigger in susceptible individuals.

Primary Causes

No single cause. Arises from a hypersensitive fear network in the brain (amygdala, medial prefrontal cortex) that misinterprets somatic sensations as catastrophic threats. Suffocation false alarm theory suggests hypersensitive brainstem CO2 receptors trigger sudden hyperventilation and panic.

• Genetics: Having a first-degree relative with panic disorder significantly increases risk.
• Temperament: High levels of neuroticism and anxiety sensitivity (belief that anxiety symptoms are harmful).
• Substance Use: High caffeine intake, nicotine use, or withdrawal from alcohol/sedatives can trigger attacks.

The pathophysiologic mechanism centers on the 'fear network' of the brain. An innocuous somatic trigger (e.g., mild tachycardia) is perceived by the interoceptive cortex and relayed to the amygdala. The amygdala initiates a massive, disproportionate sympathetic nervous system response via the locus coeruleus (releasing norepinephrine). This causes the profound physical symptoms. The prefrontal cortex fails to exhibit normal top-down inhibitory control over the amygdala, allowing the panic response to escalate rapidly.

Characteristic Clinical Presentation

• Palpitations/Tachycardia: Pounding heart, accelerated heart rate.
• Dyspnea: Sensation of shortness of breath or smothering.
• Chest Pain: Discomfort or pain in the chest mimicking cardiac ischemia.
• Derealization/Depersonalization: Feeling detached from oneself or feeling that reality is distorted.
• Fear of Dying: Overwhelming terror and impending sense of doom or losing control.

Physical Examination Signs

• Diaphoresis (excessive sweating)
• Trembling or shaking
• Hyperventilation resulting in carpopedal spasms (due to respiratory alkalosis)

• Agoraphobia: Develops in 30-50% of untreated cases, severely restricting autonomy.
• Substance Use Disorders: Self-medication with alcohol or benzodiazepines leading to dependence.
• Major Depressive Disorder: Highly comorbid, occurring in 50-60% of patients over their lifetime.

Diagnostic Criteria & Guidelines

DSM-5 criteria require: Recurrent, unexpected panic attacks comprising ≥4 of 13 specific symptoms (palpitations, sweating, trembling, shortness of breath, choking feeling, chest pain, nausea, dizziness, chills/heat, paresthesias, derealization, fear of losing control, fear of dying). AND at least one of the attacks has been followed by ≥1 month of persistent concern about additional attacks or a significant maladaptive change in behavior.

Differential Diagnosis

• Acute Myocardial Infarction / Arrhythmias (e.g., SVT)
• Pulmonary Embolism
• Hyperthyroidism
• Pheochromocytoma
• Substance-induced anxiety (e.g., cocaine, amphetamines, caffeine)

Laboratory Tests & Biomarkers

• TSH: Normal (must rule out hyperthyroidism).
• ECG: Normal sinus rhythm or sinus tachycardia (must rule out arrhythmias/ischemia).
• Urine Toxicology: Negative for illicit stimulants.

Imaging Modalities & Findings

• None routinely indicated:

• Subclinical
  Infrequent, isolated panic attacks without subsequent anticipatory anxiety.
• Uncomplicated Panic Disorder
  Recurrent attacks with persistent worry about future attacks, but no significant avoidance.
• Panic Disorder with Agoraphobia
  Extensive avoidance behavior (e.g., refusing to leave home) due to fear of having an attack.

Second-Line & Adjunctive Therapy

Tricyclic antidepressants (e.g., Imipramine). Benzodiazepines (e.g., Clonazepam 0.25-0.5 mg BID or Alprazolam 0.5 mg TID) can be used for short-term acute stabilization while waiting for SSRIs to take effect (usually 4-6 weeks), but long-term use is discouraged due to tolerance and dependence.

Surgical & Procedural Management

None.

Recommended Lifestyle Changes

Patient Counseling & Advice

Educate the patient that panic attacks, while intensely uncomfortable and terrifying, are not physically dangerous or life-threatening. Explain the 'fight or flight' response. Emphasize that SSRIs take 4-6 weeks to work and might cause a slight increase in anxiety during the first week. Warn against self-medicating with alcohol.

Follow-Up & Monitoring Schedule

Review patient every 1-2 weeks initially to monitor tolerability of SSRIs and assess suicide risk. Once stable, review every 1-3 months. Maintenance therapy is recommended for at least 12-24 months after symptom remission.

Preventive Strategies

Early intervention with CBT for individuals experiencing subclinical panic attacks can prevent progression to full panic disorder and agoraphobia.

Highly treatable. With adequate CBT and pharmacotherapy, 70-90% of patients experience significant improvement or complete remission. However, relapse can occur, especially if medications are discontinued abruptly or without concurrent CBT.